Managing strategies for lung, head and neck cancer

vandetanib improves PFS in thyroid cancer

Raising awareness about head and neck cancer through the Make Sense campaign

Targeted therapy for iodine-refractory thyroid cancer

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Second-line afatinib significantly improves PFS in metastatic head and neck cancer

Networking and collaborating across borders in sub-Saharan Africa

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

ASCO 2014 roundup

Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Phase II trial shows dacomitinib benefits a subgroup of patients with head and neck cancer